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A B S T R A C T
Background
Non-specific cough is defined as non-productive cough in the absence of identifiable respiratory disease or known aetiology. It is
commonly seen in paediatric practice. These children are treated with a variety of therapies including a variety of asthma medications.
The leukotriene pathway is reported to be involved in the sensory (neurogenic) pathway, which is a mechanism thought to be involved
in the pathogenesis of chronic cough.
Objectives
To evaluate the effectiveness of leukotriene receptor antagonist (LTRA) in treating children with prolonged non-specific cough.
Search methods
TheCochrane Register of Controlled Trials (CENTRAL), theCochrane Airways Group Specialised Register,MEDLINE and EMBASE
databases were searched by the Cochrane Airways Group. The latest searches were carried out in October 2010.
Selection criteria
All randomised controlled trials comparing LTRA with a placebo medication in children with non-specific cough.
Data collection and analysis
Results of searches were reviewed against pre-determined criteria for inclusion. Two eligible trials that utilised montelukast were
identified but no data was available for meta-analysis. It was not possible to separate results from children with non-specific cough from
those without in one study and in the second, the groups were very small (5 in montelukast group and one in placebo group).
Main results
There was no significant difference in all study endpoints between the montelukast and placebo groups (total N=256 plus 6 from
second study).
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Authors’ conclusions
With the lack of evidence, the routine use of LRTA in treating children with non-specific cough cannot be recommended.
P L A I N L A N G U A G E S U M M A R Y
Leukotriene receptor antagonist for prolonged non-specific cough in children
Children with non-specific cough (dry and non-productive cough without any other respiratory symptom, sign or systemic illness)
are commonly treated with a variety of medications to treat the symptom of cough. This review examined whether there was any
evidence for using leukotriene receptor antagonist in children with non-specific cough. There were two randomised controlled trials
that included, but was not restricted to, children with non-specific cough, whereby no significant advantage over placebo was found in
both studies. There is no RCT evidence to support the routine use of leukotriene receptor antagonist for the symptom of non-specific
cough in children. Further research examining the effects of this treatment using child appropriate cough outcome measures is needed.
B A C K G R O U N D
Cough is the most common symptom presenting to general prac-
titioners (Britt 2002; Cherry 2003) and causes significant anxi-
ety to parents (Cornford 1993). Worldwide the desire to reduce
the impact of the symptom of cough is reflected in the billions
of dollars spent on over the counter cough and cold medications.
Non-specific cough has been defined as non-productive cough in
the absence of identifiable respiratory disease or known aetiology
(Chang 2001). While some children with chronic non-specific
cough have asthma, the majority do not (McKenzie 1994; Chang
1999). In adults, chronic cough is defined as cough of over 8 weeks
duration but the definition commonly accepted in children is that
of over 3-4 weeks, based on the known differences between pae-
diatric and adults cough (Chang 2005b).
The leukotriene pathway is reported to be involved in the sen-
sory (neurogenic) pathway (Ishikawa 1996) which is a key mecha-
nism thought to be involved in the pathogenesis of chronic cough
(Mazzone 2004;Widdicombe 1995). Although leukotriene recep-
tor antagonists (LTRA) are now primarily used for asthma, they
have also been shown to reduce respiratory symptoms associated
with post respiratory syncytial virus (RSV) infection (Bisgaard
2003). The influence of LTRA in post RSV bronchiolitis is likely
through the effect of LTRA on the neurogenic pathway, as demon-
strated in animal work (Wedde-Beer 2002).While post RSV bron-
chiolitis symptoms do not constitute non-specific cough, a simi-
lar mechanism involving the neurogenic pathway maybe involved
in the pathophysiology of chronic non-specific cough. Thus it is
biologically plausible that LTRA may be beneficial in non-specific
cough (separate to its anti-asthma properties) through its action
on the neurogenic pathway. However like all medications, use of
LTRAs may cause adverse events. A systematic review of the bene-
fits (or otherwise) of LTRA on chronic non-specific cough would
thus be useful to help guide clinical practice.
O B J E C T I V E S
To evaluate the effectiveness of LTRA in treating children with
prolonged non-specific cough.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials comparing LTRA with a placebo
medication with cough as an outcome, where cough is not pri-
marily related to an underlying respiratory disorder such as cystic
fibrosis, asthma, suppurative lung disease etc.
Types of participants
Children with chronic (>4 weeks) non-specific cough (dry and
non-productive cough without any other respiratory symptom,
sign or systemic illness).
Exclusion criteria: cough related to mycoplasma, pertussis and
chlamydia, presence of underlying cardio-respiratory condition,
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current or recurrent wheeze (>2 episodes), presence of other res-
piratory symptoms (productive or wet cough (Chang 2005a),
haemoptysis, dyspnoea), presence of other respiratory signs (club-
bing, chest wall deformity, respiratory noises such as wheeze on
auscultation and other adventitious sounds), presence of any sign
of systemic illness (failure to thrive, aspiration, neurological or de-
velopmental abnormality), presence of lung function abnormality.
Types of interventions
All randomised controlled comparisons of any type of LTRA. Tri-
als only comparing two or more medications without a placebo
comparison group will not be included. Trials that included the
use of other medications or interventions were to be included if all
participants had equal access to suchmedications or interventions.
Types of outcome measures
Primary outcomes
Proportions of participantswhowere not cured or not substantially
improved at follow up (clinical failure).
Secondary outcomes
1. Proportions of participants who were not cured at follow
up,
2. Proportions of participants who not substantially improved
at follow up,
3. Mean difference in cough indices (cough diary, cough
frequency, cough scores),
4. Proportions experiencing adverse effects of the intervention,
(e.g. seizures, school performance etc),
5. Proportions experiencing complications e.g. requirement
for medication change, etc.
The proportions of participants who failed to improve on treat-
ment and the mean clinical improvement were to be determined
using the following hierarchy of assessment measures (i.e. where
two or more assessment measures are reported in the same study,
the outcomemeasure that is listed first in the hierarchywould have
been used).
i) Objective measurements of cough indices (cough frequency,
cough receptor sensitivity).
ii) Symptomatic (Quality of life, Likert scale, visual analogue scale,
level of interference of cough, cough diary) - assessed by the patient
(adult or child)
iii) Symptomatic (Quality of life, Likert scale, visual analogue scale,
level of interference of cough, cough diary) - assessed by the par-
ents/carers.
iv) Symptomatic (Likert scale, visual analogue scale, level of inter-
ference of cough, cough diary) - assessed by clinicians.
v) Relevant airway markers consistent with inflammation.
Search methods for identification of studies
The latest searches were carried out in October 2010.
Electronic searches
The following topic search strategy was used to identify the rele-
vant randomised controlled trials listed on the electronic databases:
“cough” OR “bronchitis”, all as (textword) or (MeSH ) AND
“leukotriene receptor” OR “leukotrienes” OR “montelukast” OR
“LTRA” OR “zafirlukast”, OR “pranlukast”; all as (textword) or
(MeSH) (see Appendix 1)
Trials were identified from the following sources:
1. The Cochrane Central Register of Controlled Trials
(CENTRAL) (to search date)
2. The Cochrane Airways Group Specialised Register (all
years)
3. MEDLINE (1966 to search date). Topic search strategy
combined with the RCT search filter as outlined in the Airways
Group module.
4. OLDMEDLINE (1950 to 65). Topic search strategy
combined with the RCT search filter as outlined in the Airways
Group module.
5. EMBASE (1980 to search date).Topic search strategy
combined with the RCT search filter as outlined in the Airways
Group module.
Searching other resources
1. The list of references in relevant publication
2. Written communication with the authors of trials included
in the review.
Data collection and analysis
Selection of studies
From the title, abstract, or descriptors, two reviewers (AC, DW)
independently reviewed literature searches to identify potentially
relevant trials for full review. Searches of bibliographies and texts
were conducted to identify additional studies. From the full text us-
ing specific criteria, reviewers independently selected trials for in-
clusion. Agreement would have been measured using kappa statis-
tics. Disagreement would have been resolved by third party adju-
dication (JA).
Data extraction and management
Trials that satisfied the inclusion criteria were reviewed and the
following information was recorded: study setting, year of study,
source of funding, patient recruitment details (including number
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of eligible subjects), inclusion and exclusion criteria, other symp-
toms, randomisation and allocation concealment method, num-
bers of participants randomised, blinding (masking) of partici-
pants, care providers and outcome assessors, dose and type of in-
tervention, duration of therapy, co-interventions, numbers of pa-
tients not followed up, reasons for withdrawals from study proto-
col (clinical, side-effects, refusal and other), details on side-effects
of therapy, and whether intention-to-treat analyses were possible.
Data was extracted on the outcomes described previously. Further
information was requested from the authors of the single included
study (van Adelsberg 2005)
Assessment of risk of bias in included studies
Rias of bias table in Revman was utilised. Aditionally quality as-
sessment of the study included was independently performed by
two reviewers (AC, JA). Four components of quality were assessed:
1. Allocation concealment. Trials were scored as: Grade A:
Adequate concealment, Grade B: Unclear, Grade C: Clearly
inadequate concealment. (Grade A = high quality).
2. Blinding. Trials were scored as: Grade A: Participant and
care provider and outcome assessor blinded, Grade B: Outcome
assessor blinded, Grade C: Unclear, Grade D: No blinding of
outcome assessor (Grade A, B = high quality).
3. Reporting of participants by allocated group. Trials were
scored as: Grade A: The progress of all randomised children in
each group described, Grade B: Unclear or no mention of
withdrawals or dropouts, Grade C: The progress of all
randomised children in each group clearly not described. (Grade
A = high quality).
4. Follow-up. Trials were scored as: Grade A: Outcomes
measured in >90% (where withdrawals due to complications and
side-effects are categorised as treatment failures), Grade B:
Outcomes measured in 80-90%, Grade C: Unclear, Grade D:
Outcomes measured in <80%. (Grade A = high quality).
While only the allocation concealment quality assessment would
have been displayed in the meta-analysis figures, all assessments
were included in the ’Characteristics of included studies’ table.
Measures of treatment effect
It was planned that the dichotomous outcome variables of each
individual study, relative and absolute risk reductions will be cal-
culated using a modified intention-to-treat analysis. This analy-
sis would have assumed that children not available for outcome
assessment have not improved (and probably represents a con-
servative estimate of effect). An initial qualitative comparison of
all the individually analysed studies of all the individually anal-
ysed studies to examine whether pooling of results (meta-analysis)
would have been reasonable was planned. This would have taken
into account differences in study populations, inclusion/exclusion
criteria, interventions, outcome assessment, and estimated effect
size.
Data synthesis
The results from studies that met the inclusion criteria and re-
ported any of the outcomes of interest would have been included
in the subsequent meta-analyses. The summary weighted risk ra-
tio and 95% confidence interval (fixed-effect model) would have
been calculated (Cochrane statistical package, RevMan 4.2). For
cross-over studies, mean treatment differences would have been
calculated from raw data, extracted or imputed and entered as
fixed effects generic inverse variance (GIV) outcome, to provide
summary weighted differences and 95% confidence intervals. In
cross-over trials, only data from the first arm would have been
included in meta analysis if data is combined with parallel studies
(Elbourne 2002). Numbers needed to treat (NNT) would have
been calculated from the pooled OR and its 95% CI applied to a
specified baseline risk using an online calculator (Cates 2003). The
cough indices would have been assumed to be normally distributed
continuous variables so the mean difference in outcomes could
be estimated (weighted mean difference). If studies reported out-
comes using different measurement scales, the standardised mean
difference would have been estimated. Any heterogeneity between
the study results would have been described and tested to see if it
reached statistical significance using a chi-squared test. The 95%
confidence interval estimated using a random-effectsmodel would
have been included whenever there are concerns about statistical
heterogeneity.
Subgroup analysis and investigation of heterogeneity
An a priori sub-group analysis was planned for children aged less
than seven years and seven years and above.
Sensitivity analysis
Sensitivity analyses were planned to assess the impact of the po-
tentially important factors on the overall outcomes:
a) study quality;
b) study size;
c) variation in the inclusion criteria;
d) differences in the medications used in the intervention and
comparison groups;
e) differences in outcome measures;
f ) analysis using random effects model;
g) analysis by ’treatment received’;
h) analysis by ’intention-to-treat’; and
R E S U L T S
Description of studies
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See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The Airways Group Specialised Register/search identified 226 po-
tentially relevant titles in the original search (2005). After assessing
the abstracts, 24 papers were retrieved and five potential studies
were considered (see Characteristics of excluded studies). For the
2006 and 2007 updates, a further 62 and 40 abstracts were re-
viewed but no study fulfilled inclusion criteria. The 2008 search
identified 63 abstracts of which 5 were obtained but none fulfilled
inclusion criteria. The 2009 search identified 62 potential stud-
ies from which 9 papers were fully reviewed and only one study
(Kooi 2008) had subjects that fulfilled inclusion criteria. Of the
54 potential titles in the 2010 search, 4 papers were described in
the ’excluded studies’ list.
Two studies (van Adelsberg 2005, Kooi 2008) fulfilled the eligi-
bility criteria. Although the term ’asthma symptoms’ which in-
cluded cough was an inclusion criteria in the first included study
(van Adelsberg 2005), it is likely that a number of children would
not have fulfilled study criteria of non-specific cough. Data were
sought from the corresponding author of the trial but none was
received. The study was designed primarily for safety and toler-
ability of montelukast but analysis included clinical efficacy (see
Characteristics of included studies). The study was supported and
reported by a commercial interest. The second study (Kooi 2008)
included children with cough alone and hence fulfilled inclusion
criteria. Raw data provided by the primary author revealed 11
children were in the ’cough only’ subgroup of which only 6 (5 in
montelukast group and one in placebo group) could be included
for this review.
Risk of bias in included studies
Both studies (van Adelsberg 2005,Kooi 2008) scored ’high quality’
in two categories of the Quality Assessment scale. See also ’risk of
bias table’
Effects of interventions
One study included 256 randomised subjects (van Adelsberg
2005). There was no difference in all study endpoints between the
montelukast and placebo groups. As it was not possible to sepa-
rate children with non-specific cough from those without, no data
have been presented in the MetaView. Cough was not reported as
an outcome measure, thus cough-specific related outcomes can-
not be described. Clinical adverse events were also not different
between groups and no serious adverse events occurred in either
group. The second study (Kooi 2008) included in this review had
a subgroup that fulfilled the criteria (cough only). Relevant data
obtained from the raw results provided by the primary data are
displayed in the analysis were but the effect of the intervention
could not be estimated as the sample size was too small (n=6).
D I S C U S S I O N
Two randomised controlled trial comparing LTRA with a placebo
in children with non-specific cough were identified. These stud-
ies were included as the inclusion criteria included children with
isolated cough (van Adelsberg 2005, Kooi 2008). The authors in-
cluded symptoms described as ’asthma symptoms’ but it is highly
controversial if the diagnosis of asthma can be made in the age
group (6-24 months) studied (Strunk 2002). However it is likely
that only some of the children in the study would have fulfilled
the study criteria.
No difference between groups was found in both clinical effi-
cacy or in adverse events in both studies (van Adelsberg 2005,
Kooi 2008). In comparison to RCTs in adults (Dicpinigaitis 2002,
Spector 2004) using LTRA for cough outcomes whereby LTRAs
were found to be effective, this review is inconclusive despite
the significantly larger sample size (n=256) in the included study
(van Adelsberg 2005) when compared to the study in adults
(Dicpinigaitis 2002, Spector 2004) (n= 8 and 14 respectively).
A single cohort study (Kopriva 2004) was also found whereby the
time to response was within 3 weeks (mainly within 2 weeks).
However this has to interpreted in the context of methodological
problems in studieswith cough as anoutcomemeasure, specifically
the large placebo effect, biased subjective reporting, and period
effect (Chang 1999). Given the morbidity associated with chronic
cough in children, there is a need for the evaluation of the efficacy
of LTRA on non-specific cough in children.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
With the lack of evidence, the routine use of LRTA in treating chil-
dren with non-specific cough cannot be recommended. If LTRA
were to be trialled in these children, current cohort data suggest a
clinical response (subjective cough severity) usually occurs within
two weeks of therapy and definitely within three weeks.
Implications for research
Randomised controlled trials of LTRA to determine the effec-
tiveness in treating children with non-specific cough are clearly
needed. Trials should be parallel studies and double blinded, given
the known problems in studying cough, specifically the large
placebo and time period effects (Chang 1999). Based on cohort
data, a short trial of three weeks would suffice. Outcomemeasures
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for the clinical studies on cough should be clearly defined using
validated subjective data (including quality of life) and supported
by objective data if possible.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Kooi 2008
Methods Multicenter, randomized, placebo-controlled, double-blind, double-dummyparallel trial
ICS or LTRA use was not allowed for a period of 4 weeks preceding the trial. Other
exclusion criteria were as follows: use of systemic corticosteroids in the last 2 months;
hospitalization for asthma-related symptoms
in the last 2weeks; respiratory disorders other than asthma and poorly controlled systemic
diseases. Subsequently, eligible children entered a run-in period of 2 weeks in which the
caregivers of the child recorded their child’s respiratory symptoms in a diary. Children
with symptoms on less than 4 days of the
2-week run-in period or children who used anti-inflammatory medication in this period
were excluded at the second visit
Quality Assessment: B, A, A, B; high quality score of 2.
Participants Children were recruited from three outpatient clinics (secondary care) in The Nether-
lands. Children aged
2-5 years with asthma-like symptoms (wheeze, cough and/or shortness of breath) of
sufficient severity to justify the use of prophylactic asthma treatment were eligible for
inclusion.63 aged 2-6 years with asthma-like symptoms were included
Number of participants in whole study: Fluticasone (n=25), Montelukast (n=18) or
placebo (n=20). Mean age (years and SD) in respective groups were 3.8 (71.4) 3.9 (71.
1) and 3.8 (71.3) respectively
Number of ’cough only’ participants in study: Fluticasone (n=5), Montelukast (n=5) or
placebo (n=1)
Interventions Fluticasone (100 ug twice daily via metered dose inhaler and a spacer (Aerochamber)),
Montelukast (4mg daily) or placebo (dummy MDI and dummy tablet) for 3 months
Outcomes The primary outcome was the daily symptom score (wheeze, cough, shortness of breath)
as recorded by caregivers in a symptom diary card which were filled out twice daily during
the run-in period and 1
month prior to each follow-up visit. Parents rated their child’s night-time and day-time
symptoms (cough, wheeze and shortness of breath) on a scale from 0 (no symptoms) to
3 (severe symptoms) each morning and evening. Thus, the total daily symptom score
ranged from 0 to 18
Secondary endpoints were rescue medication free days, blood eosinophils and lung func-
tion (interrupter technique and forced oscillation technique (FOT)). Data on rescue
medication use were derived from the dairy card. The percentage of days on which no
rescue medication (salbutamol) was used was calculated. Eosinophils were measured in
venous blood at baseline and after 3 months. Lung function was measured using two
non-invasive techniques: the interrupter technique and the FOT
Adverse events and concomitant medication use were obtained from the diary card
Notes Raw data relevant to children with cough and no wheeze were kindly provided by Dr
Kooi
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Kooi 2008 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear Not described in paper
Blinding?
All outcomes
Yes Double blinded, double dummy trial
Incomplete outcome data addressed?
All outcomes
Yes Drop-outs and reasons provided
Free of selective reporting? Yes
Free of other bias? Yes Baseline data for groups (montelukast vs
placebo) were similar. Study supported by
Merck Sharp andDohme (manufacturer of
montelukast) but authors had no financial
conflicts of interest
van Adelsberg 2005
Methods Randomised, double blind, placebo-controlled, parallel, multicentre study, comparing
6 weeks of montelukast with placebo in children aged 6-24 months with ’asthma symp-
toms’ including cough. The study was designed primarily for safety and tolerability of
montelukast; number allocated to montelukast to placebo was 2:1. Study was carried
out, supported and reported by a commercial interest (Merck Research Laboratories)
Randomisation by computer generated schedule, method of blinding and allocation
concealment not described. Adherence not mentioned. Dropouts: montelukast=6 (3.
4%), placebo= 7 (8.4%)
Quality Assessment: B, A, A, B; high quality score of 2.
Participants 256 children (359 screened) aged 6-24 months were recruited from 65 centres (Africa,
Asia, Europe, North America, South America). Participants were reviewed 2 weekly.
Method of recruitment not specified
Montelukast group: 51 (29%) aged 6-12 months, 124 (70.9%) aged 12.1-24 months;
59 boys, 22 girls. Placebo group: 33 (40.7.%) aged 6-12 months, 48 (59.3%) aged 12.
1-24 months; 116 boys, 59 girls
Inclusion criteria: history of ’asthma-like’ symptoms, including but not limited to cough,
wheezing, and shortness of breath; or a history of physician-diagnosed asthma
Exclusion: born premature, unresolved respiratory tract infection, any serious condition
requiring hospitalisation or emergency room visits in the within 4 weeks, or an asthma
exacerbation within 2 weeks of pre-study visit
Interventions 6 weeks of 4mg montelukast (oral granules) or matching placebo, given once a day. Trial
medications were given with one tablespoon of apple sauce at bedtime
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van Adelsberg 2005 (Continued)
Outcomes Safety and tolerability of trial medications. Secondary endpoints were efficacy endpoints:
days without beta agonist use, beta agonist use per day, total peripheral blood eosinophil
count, number of unscheduled physician, emergency room or hospital visits due to wors-
ening ’asthma’ symptoms, oral corticosteroid rescues for asthma’ symptoms, asthma at-
tacks (composite of unscheduled visits and oral steroid rescues) and discontinuations due
to worsening ’asthma symptoms’. Carers recorded details daily on a modified calender.
Authors considered secondary endpoints exploratory outcomes
Notes Study was included as cough was an inclusion factor and diagnosis of asthma in the age
group of participants is controversial
Study’s primary author was contacted but did not respond to request for additional data
Risk of bias
Item Authors’ judgement Description




Incomplete outcome data addressed?
All outcomes
Yes
Free of selective reporting? Yes
Free of other bias? Unclear Study was carried out, supported and re-
ported by a commercial interest (MerckRe-
search Laboratories)
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bisgaard 2003 Young children (3-36 months) were recruited from hospitalised episodes of bronchiolitis. Hence children did
not have non-specific cough
Dicpinigaitis 1999 Study in healthy adults
Dicpinigaitis 2002 RCT cross-over design in 8 adults on the effect of a 14-day course zafirlukast on subjective cough score and
cough-reflex sensitivity
Ghosh 2006 Non RCT. Some children’ with cough variant asthma’ were included in the study but the study was not a
randomised controlled study
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(Continued)
Hallstrand 2002 RCT using montelukast and loratadine or placebo for exercise induced bronchoconstriction in adults
He 2009 Case control study involving 4 weeks of terbutaline and montelukast compared to terbutaline
Jung 2006 Non-placebo control study comparing inhaled budesonide (nebulised 500ug bd), montelukast and salbutamol
Kawai 2008 Non-RCT in adults
Kita 2010 Study on adults with ’atopic cough’ randomised to montelukast or placebo, and ’cough variant asthma’ ran-
domised to montelukast, clenbuterol, or montelukast plus clenbuterol
Kopriva 2004 Non randomised trial. Cohort study on 22 children given montelukast (5mg daily) for 4 weeks. Cough ceased
in 14 (68%) of children by week 3 of treatment
Kowal 2006 Study on adults with asthma
Lehtimaki 2009 A randomised, double-blind, placebo-controlled crossover study on the effect ofmontelukast in atopic syndrome.
Cough was not an outcome measure
Proesmans 2009 Study on young children randomised to montelukast or placebo post bronchiolitis. Study found no statistical
significant differences between the two groups for symptom-free (cough and wheeze) days and nights
Shimonda 2006 Non placebo trial
Spector 2004 RCT in 14 adults with a 7- to 10-day baseline period and a 4-week treatment period with montelukast, 10 mg,
or placebo daily
Yamaguchi 2009 Study on adults with ’cough variant asthma’. Participants randomly assigned to receive daily doses of budesonide
(BUD) 400 mcg (n=22), BUD 1200 mcg (22) or montelukast 10 mg
Zedan 2009 Prospective case control study comparing montelukast to fluticasone for reducing symptoms (including cough)
and other asthma markers in children
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D A T A A N D A N A L Y S E S
Comparison 1. Cough outcomes




participants Statistical method Effect size
1 Day-time cough 1 6 Mean Difference (IV, Fixed, 95% CI) Not estimable
2 Night-time cough 1 6 Mean Difference (IV, Fixed, 95% CI) Not estimable
Comparison 2. Rescue medications




participants Statistical method Effect size
1 Salbutamol use 1 6 Mean Difference (IV, Fixed, 95% CI) Not estimable
Analysis 1.1. Comparison 1 Cough outcomes, Outcome 1 Day-time cough.
Review: Leukotriene receptor antagonist for prolonged non-specific cough in children
Comparison: 1 Cough outcomes
Outcome: 1 Day-time cough





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kooi 2008 5 13 (7.25) 1 25 (0) Not estimable
Total (95% CI) 5 1 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours experimental Favours control
12Leukotriene receptor antagonist for prolonged non-specific cough in children (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 Cough outcomes, Outcome 2 Night-time cough.
Review: Leukotriene receptor antagonist for prolonged non-specific cough in children
Comparison: 1 Cough outcomes
Outcome: 2 Night-time cough





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kooi 2008 5 9 (9.75) 1 25 (0) Not estimable
Total (95% CI) 5 1 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
Analysis 2.1. Comparison 2 Rescue medications, Outcome 1 Salbutamol use.
Review: Leukotriene receptor antagonist for prolonged non-specific cough in children
Comparison: 2 Rescue medications
Outcome: 1 Salbutamol use





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kooi 2008 5 3.2 (5.63) 1 0 (0) Not estimable
Total (95% CI) 5 1 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours experimental Favours control
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A P P E N D I C E S
Appendix 1. Search strategies
Database Search
CENTRAL #1. COUGH single term (MeSH)
#2. BRONCHITIS explode tree 1 (MeSH)
#3. cough*
#4. bronchiti*
#5. (#1 or #2 or #3 or #4)







#13. (anti next leukotriene*)
#14 pranlukast*
#15. (#6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14)
#16. (#5 and #15)
MEDLINE/OLDMEDLINE

















16. 5 and 15
EMBASE
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16. 5 and 15
Airways Group Register (cough* or bronchiti*) AND (leukotriene* or leucotriene* or anti-
leukotriene* or anti-leucotriene* or montelukast* or zafirlukast*
or pranlukast* or LTRA)
WH A T ’ S N E W
Last assessed as up-to-date: 28 October 2010.
Date Event Description
29 October 2010 New search has been performed Updated search. No new studies included
H I S T O R Y
Protocol first published: Issue 1, 2006
Review first published: Issue 4, 2006
Date Event Description
25 October 2009 New search has been performed New search and new study added
24 March 2009 Amended Contact details changed
24 October 2008 New search has been performed Literature search re-run; no new studies found
23 October 2008 New search has been performed No new studies
1 August 2008 Amended Converted to new review format.
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C O N T R I B U T I O N S O F A U T H O R S
For the protocol: Protocol was written by AC, based on previous protocols on cough in children. JW and DW reviewed protocol. For
the review: AC: selection of articles from search, data extraction, data analysis and writing of review. JA and DW: selection of articles
from search, review of articles for inclusion, and writing of review.
D E C L A R A T I O N S O F I N T E R E S T
None declared.
S O U R C E S O F S U P P O R T
Internal sources
• Royal Children’s Hospital Foundation, Brisbane, Australia.
External sources
• National Health and Medical Research Council, Australia.
Salary support for AC (grant number 545216)
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acetates [∗therapeutic use]; Cough [∗drug therapy]; Leukotriene Antagonists [∗therapeutic use]; Quinolines [∗therapeutic use]
MeSH check words
Child; Humans
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